Black Diamond Therapeutics (BDTX) Total Current Liabilities (2018 - 2026)

Black Diamond Therapeutics (BDTX) has reported Total Current Liabilities for 9 consecutive years, with $15.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 5.72% year-over-year to $15.8 million; the trailing twelve-month figure through Jun 2026 stood at $15.8 million (down 5.72% YoY), and the FY2025 full-year result was $15.7 million, down 23.54% from the prior year.
• Total Current Liabilities improved to $15.8 million in Q2 2026 per BDTX's latest filing, from $14.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $21.1 million in Q3 2022 and bottomed at $12.8 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $17.2 million across 5 years, with a median of $16.8 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities tumbled 35.45% in 2022, then soared 38.06% in 2024.
• Over 5 years, Total Current Liabilities stood at $15.3 million in 2022, then rose by 28.73% to $19.6 million in 2023, then increased by 4.72% to $20.6 million in 2024, then decreased by 23.54% to $15.7 million in 2025, then climbed by 0.71% to $15.8 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $15.8 million, $14.5 million, and $15.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.